Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497778 | 0.90 | PHLPP2 (0.45) | PHLPP2LTB4RLTB4R2SIGMAR1OPRK1 | |
| SCHEMBL15652035 | 0.83 | LTB4R (0.43) | PHLPP2LTB4RLTB4R2SIGMAR1OPRK1 | |
| SCHEMBL17011380 | 0.79 | OPRK1 (0.41) | LTB4RLTB4R2SIGMAR1OPRK1 | |
| SCHEMBL17011382 | 0.79 | SIGMAR1 (0.46) | PHLPP2LTB4RLTB4R2SIGMAR1OPRK1 | |
| SCHEMBL4490731 | 0.79 | SIGMAR1 (0.63) | TSHRSIGMAR1OPRK1 | |
| SCHEMBL4052270 | 0.77 | NUDT1 (0.49) | PHLPP2TSHROPRK1LMNA | |
| SCHEMBL4488661 | 0.77 | PHLPP2 (0.53) | PHLPP2TSHRLMNA | |
| SCHEMBL12460026 | 0.77 | OPRK1 (0.44) | LTB4RLTB4R2SIGMAR1OPRK1LMNA | |
| SCHEMBL12460081 | 0.75 | OPRK1 (0.43) | LTB4RLTB4R2SIGMAR1OPRK1 | |
| SCHEMBL12460089 | 0.75 | HPGD (0.51) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | PHLPP2 1485/4885LTB4R 1011/4885LTB4R2 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.